Abstract 1502P
Background
Rectal cancer treatments have improved significantly over the past two decades, leading to higher survival rates. However, there's a growing emphasis on the long-term quality of life for survivors, including addressing sexual health needs. Our study aims to evaluate QOL, particularly sexual dysfunction, using validated tools like EORTC QLQ-C30, QLQ-CR29, and GRISS, aiming to improve care for rectal cancer patients.
Methods
Validated questionnaires (EORTC QLQ-C30, QLQ-CR29, GRISS) were completed by participants, assessing various aspects of quality of life and sexual satisfaction. Statistical analyses included tests for normality, descriptive analyses of patient characteristics, correlation analyses between questionnaire scores, and comparison of median scores using appropriate tests.
Results
The study included a total of 83 participants. Mean age of 55.95 ± 11.53, predominantly under 65 years (79.5%). A majority of patients (65.1%) had a stoma, and 78.3% underwent surgery, with 67.5% retaining sphincter function. The cohort was divided into non-metastatic (60.2%) and metastatic (39.8%) groups Significant correlations were observed between the Golombok Total Score and various subscores of the C30 scale. The fatigue subscore correlated positively with Golombok-female Total Score (r=0.331, p=0.041) and Golombok-male Total Score (r=0.370, p=0.042). Body image (p
Conclusions
This study demonstrates the profound and varied impact of rectal cancer treatment on patients' sexual health and overall quality of life, particularly affected by the presence of a stoma and metastatic disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10